Research published today shapes medical treatment, infrastructure, legislation, and the datasets training the next generation of AI. When something false enters the record, the damage compounds for years before anyone catches it.
20/20 turns review from a manual judgment call into a context-backed decision. Instead of relying on whoever happens to be checking, it equips people with verified citation data, claim-level evidence, and integrity signals before they read a single line. Human judgment goes first. 20/20 never overrides it.
AI produces fluent, fully-referenced work faster than any human system can check it. The material looks finished, which is exactly what makes it easy to stop looking. And the consequences compound.
Five stages analyze every citation, every claim, and every assertion against the open scientific literature. Everything in between is deterministic and auditable. Watch each stage work below.
20/20 does not replace reviewers, and it does not generate anything. It is not an LLM. It is a deterministic verification engine: it calculates whether claims actually hold against the published record. No hallucination, no invented sources, no verdicts. What it removes is the invisible burden: finding what is missing, checking what cannot be verified by hand, and surfacing what a submission chose not to tell you. Then it hands the decision back to the person who should be making it.
A simulated view of 20/20 working alongside a reviewer: manuscript on the left, the 20/20 report in the center, the reviewer writing their own notes on the right. Every name, journal, and reference below is fictional.
Nanoparticle-mediated drug delivery in glioblastoma: a systematic review
Submitted · International Review of Biomedical Systems · 2026
Recent studies demonstrate that nanoparticle carriers achieve 94% blood-brain barrier penetration rates in vivo, a significant therapeutic advance over conventional approaches. Solvenn et al. (2026) established the definitive therapeutic window for temozolomide encapsulation at 40-60nm particle diameter, a finding corroborated by six independent meta-analyses. Furthermore, no published study has reported adverse hippocampal tissue accumulation at doses below 5mg/kg. The blood-brain barrier presents unique challenges for chemotherapeutic delivery that nanoparticle engineering has increasingly addressed.Claims, sources, and entailment look the same in a court filing, a regulatory dossier, or a policy memo. Verification generalizes. Academic peer review is where we start, not where we stop.
We are running a limited pilot with journals and editorial teams: real submission queues, measured against your current process. Drop your email and we will be in touch.
Insights on the replication crisis, AI-generated research, and what happens when the record breaks down.